The article presents the results of a study on the bioaccumulation abilities of , a red algae specific to the southern Baltic Sea, towards (of) gamma emitting isotopes. A laboratory experiment was carried out to determine changes in the activities of some isotopes-Mn, Co, Zn, Ag,Sn, Cs, Cs and Am-occurring in exposed to a seawater medium containing these isotopes over the course of 1 month. All analyzed isotopes showed the greatest increase of radioactive activity in plant tissue in the first 24 h of exposure. The temporary concentration factors of cesium isotopes were increasing linearly during the experiment from 114 to 274 in the case of Cs, and from 144 to 351 in the case of Cs. The level of the initial concentration factor of cesium isotopes in the plant proved to be independent of the initial concentration of the isotope in seawater and it took the lowest (125 dm kg) level among the studied isotopes. In the case of a mixture of gamma emitting isotopes, a linear relation between the individual isotope activity in and its initial concentration in seawater was established after the first day of exposure; the isotopes initial concentration factors ranged from 767 to 874 dm kg. Having reached the maximal concentration level, a statistically significant decline in radioactivity concentrations of the five isotopes in the plant tissue was observed. A half-life of biological removal of the isotopes from the plant tissue was established at: 3.8 days in the case of Mn, 4 days-Co, 4 days-Co, 4.2 days-Cs and Am-3.5 days.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514610 | PMC |
http://dx.doi.org/10.1007/s10967-013-2794-2 | DOI Listing |
Clin Rheumatol
January 2025
Department of Public Health, University of Murcia, Campus de Ciencias de la Salud, Murcia, 30120, Spain.
Introduction: Therapeutic drug monitoring (TDM) in inflammatory rheumatic diseases (RMDs) is gaining interest. However, there are unresolved questions about the best practices for implementing TDM effectively in clinical settings.
Objective: The primary objective of this study was to evaluate whether early TDM of adalimumab predicts drug survival at 52 weeks in patients with RMDs.
BMC Med Educ
January 2025
Boston University School of Public Health, 715 Albany St, Boston, MA, 02118, USA.
Background: Healthcare resources have been concentrated in urban areas, leaving rural regions vulnerable to poorer health outcomes. The Problem Solving for Better Health (PSBH) program was implemented to enhance healthcare systems in resource-limited regions by training personnel to maximize existing resources in problem-solving. This study evaluated the implementation effectiveness of PSBH-Nursing (PSBHN), a nationally led initiative to train nurses in PSBH in Lesotho.
View Article and Find Full Text PDFPharm Res
January 2025
BioDev Department WuXi Biologics USA, 1 Cedarbrook Dr, Cranbury, NJ, 08512, USA.
Background: High concentration protein formulation (HCPF) development needs to balance protein stability attributes such as conformational/colloidal stability, chemical stability, and solution properties such as viscosity and osmolality.
Methodology: A three-phase design is established in this work. In Phase 1, conformational and colloidal stability are measured by 384-well-based high-throughput (HT) biophysical screening while viscosity reduction screening is performed with HT viscosity screening.
Clinical trials demonstrate the short-term efficacy of dual CFTR modulators, but long-term real-world data is limited. We aimed to investigate the effects of 24-month lumacaftor/ivacaftor (LUM/IVA) therapy in pediatric CF patients (pwCF). This observational study included pwCF homozygous for F508del mutation treated between 2021 and 2023.
View Article and Find Full Text PDFSci Rep
January 2025
Department of Life Sciences, University of Modena and Reggio Emilia, Via Giuseppe Campi 103-287, 41125, Modena, Italy.
The present study was aimed at revealing the metabolic changes that occurred in the cellular lipid pattern of acute and chronic myeloid leukaemia cells following treatment with cannabidiol (CBD). CBD is a non-psychoactive compound present in Cannabis sativa L., which has shown an antiproliferative action in these type of cancer cells.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!